Advanced search
1 file | 161.63 KB Add to list

Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers

Alan Van Goethem (UGent) , Jo Vandesompele (UGent) and Tom Van Maerken (UGent)
Author
Organization
Abstract
Neuroblastoma is a rare developmental tumour of young children accounting for a disproportionally high proportion of paediatric cancer deaths. Increasing insights into neuroblastoma genetics and biology led to the identification of the MDM2 antagonist idasanutlin as a promising therapeutic strategy. In this thesis, we investigated two key aspects that could facilitate the clinical implementation of idasanutlin for the treatment of neuroblastoma patients. First, we identified the BCL2 inhibitor venetoclax as a synergistic drug partner of idasanutlin using both in vitro and in vivo model systems of neuroblastoma. Second, we discovered circulating miRNAs that dynamically respond to p53 activation in mice carrying human neuroblastoma xenografts; opening up possibilities for non-invasive treatment monitoring.

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 161.63 KB

Citation

Please use this url to cite or link to this publication:

MLA
Van Goethem, Alan, Jo Vandesompele, and Tom Van Maerken. “Pharmacological Restoration of Tumour Suppressor Protein P53 in Neuroblastoma : Seeking Synergy and Non-invasive Biomarkers.” BELGIAN JOURNAL OF MEDICAL ONCOLOGY 12.1 (2018): 26–28. Print.
APA
Van Goethem, A., Vandesompele, J., & Van Maerken, T. (2018). Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers. BELGIAN JOURNAL OF MEDICAL ONCOLOGY, 12(1), 26–28.
Chicago author-date
Van Goethem, Alan, Jo Vandesompele, and Tom Van Maerken. 2018. “Pharmacological Restoration of Tumour Suppressor Protein P53 in Neuroblastoma : Seeking Synergy and Non-invasive Biomarkers.” Belgian Journal of Medical Oncology 12 (1): 26–28.
Chicago author-date (all authors)
Van Goethem, Alan, Jo Vandesompele, and Tom Van Maerken. 2018. “Pharmacological Restoration of Tumour Suppressor Protein P53 in Neuroblastoma : Seeking Synergy and Non-invasive Biomarkers.” Belgian Journal of Medical Oncology 12 (1): 26–28.
Vancouver
1.
Van Goethem A, Vandesompele J, Van Maerken T. Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers. BELGIAN JOURNAL OF MEDICAL ONCOLOGY. 2018;12(1):26–8.
IEEE
[1]
A. Van Goethem, J. Vandesompele, and T. Van Maerken, “Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers,” BELGIAN JOURNAL OF MEDICAL ONCOLOGY, vol. 12, no. 1, pp. 26–28, 2018.
@article{8558553,
  abstract     = {Neuroblastoma is a rare developmental tumour of young children accounting for a disproportionally high proportion of paediatric cancer deaths. Increasing insights into neuroblastoma genetics and biology led to the identification of the MDM2 antagonist idasanutlin as a promising therapeutic strategy. In this thesis, we investigated two key aspects that could facilitate the clinical implementation of idasanutlin for the treatment of neuroblastoma patients. First, we identified the BCL2 inhibitor venetoclax as a synergistic drug partner of idasanutlin using both in vitro and in vivo model systems of neuroblastoma. Second, we discovered circulating miRNAs that dynamically respond to p53 activation in mice carrying human neuroblastoma xenografts; opening up possibilities for non-invasive treatment monitoring.},
  author       = {Van Goethem, Alan and Vandesompele, Jo and Van Maerken, Tom},
  issn         = {1784-7141},
  journal      = {BELGIAN JOURNAL OF MEDICAL ONCOLOGY},
  language     = {eng},
  number       = {1},
  pages        = {26--28},
  title        = {Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers},
  volume       = {12},
  year         = {2018},
}